Ascendis Pharma A/S, headquartered in Hellerup, Denmark, is a pioneering biopharmaceutical company focused on developing innovative therapies for rare diseases and endocrine disorders. Leveraging its proprietary TransCon™ technology platform, Ascendis is advancing a diverse pipeline of clinical-stage candidates designed to address critical unmet medical needs. With a strategic emphasis on sustainable growth and patient-centric solutions, the company is poised to make significant contributions to the biopharmaceutical industry, aiming to transform the treatment landscape for patients worldwide. Show more

Location: TUBORG BOULEVARD 12, HELLERUP, DENMARK, 2900, Hellerup, 2900, USA | Website: https://ascendispharma.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE


Market Cap

13.43B

52 Wk Range

$118.03 - $242.00

Previous Close

$219.73

Open

$220.31

Volume

1,331,355

Day Range

$215.51 - $227.18

Enterprise Value

13.7B

Cash

539.1M

Avg Qtr Burn

N/A

Insider Ownership

0.76%

Institutional Own.

-

Qtr Updated

09/30/25


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
SKYTROFA® (Lonapegsomatropin-tcgd) Details
Adult growth hormone deficiency

Approved

Quarterly sales

Approved

Quarterly sales

SKYTROFA (TransCon hGH) (lonapegsomatropin) Details
Pediatric growth hormone deficiency

Approved

Quarterly sales

TransCon CNP Details
Achondroplasia

PDUFA

Approval decision

TransCon hGH Details
Turner syndrome

Phase 3

Initiation

Phase 2

Data readout

TransCon IL-2 B/y Details
Cancer, Solid tumor/s

Phase 2

Data readout

Phase 2

Update

Phase 2

Update

TransCon CNP Details
Achondroplasia

Phase 2

Update